Systematic reviews

← vista completa

Published on September 1, 2012 | http://doi.org/10.5867/medwave.2012.08.5471

Effectiveness and safety of atomoxetine for ADHD in population between 6 and 19 years: a systematic review

Evaluación de la efectividad y seguridad de la atomoxetina para déficit atencional en población entre 6 y 19 años: revisión sistemática

José Calleja, José Uribarri

Abstract

Introduction: Attention deficit hyperactivity disorder (ADHD) is generally treated with pharmacological interventions such as psychostimulants. The most used widely used one is methylphenidate followed by atomoxetine. Purpose: To identify, synthesize and evaluate the best available evidence on the effectiveness and safety of atomoxetine in ADHD treatment in the 6-19 year-old population. Methods: A systematic review of intervention studies that evaluated effectiveness of atomoxetine compared with placebo and methylphenidate was conducted. Outcomes assessed were educational functioning, psychosocial functioning, quality of life and adverse effects. The search was done up to February 2012 in English and Spanish in the following databases: PubMed/MEDLINE, LILACS, Cochrane, DARE and National Guideline Clearinghouse. The articles were independently evaluated by two investigators. Results: Of the 108 studies found initially, 11 were included, among which five systematic reviews, one primary article and 5 clinical guidelines. Conclusions: Atomoxetine is recommended as a second option in ADHD and was found to be superior to placebo. Its use is recommended when methylphenidate fails or comorbidities are present.

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

José Calleja

Médico de la Clínica La Salina Petróleos de Venezuela S.A. (PDVSA), docente investigador PAS-LUZ, Universidad del Zulia, Venezuela

José Uribarri

Médico pediatra, Petróleos de Venezuela S.A. (PDVSA), Maracaibo, Venezuela

Figures

Article has no figures.

Forum

No messages

History

Citation Calleja J, Uribarri J. Effectiveness and safety of atomoxetine for ADHD in population between 6 and 19 years: a systematic review. Medwave 2012;12(08):e5471 doi: 10.5867/medwave.2012.08.5471

Submission date 29/05/2012

Acceptance date 08/08/2012

Publication date 01/09/2012

Index

Metrics

Not available at the moment.

Notes

Keywords

attention deficit disorder with hyperactivity, atomoxetine, systematic review

Origin and peer review

con 3 revisiones externas por pares: dos a doble ciego y una abierta y firmada

References

  1. DSM-IV. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 ed. Text Revision. Washington D.C.: American Psychiatric Association, 2000. | Link
  2. Preti A. Tomoxetine (Eli Lilly & Co). Curr Opin Investig Drugs. 2002 Feb;3(2):272-7. | PubMed
  3. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001 Aug 11;323(7308):334-6. | CrossRef | PubMed
  4. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry. 2008 Feb;47(2):209-18. | CrossRef | PubMed
  5. Cheng JY, Chen RY, Ko JS, Ng EM. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents: meta-analysis and meta-regression analysis. Psychopharmacology (Berl). 2007 Oct;194(2):197-209. Epub 2007 Jun 16. | CrossRef | PubMed
  6. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technology Assessment. 2006;10(23):382. | PubMed | Link
  7. Garces K. Atomoxetine for attention deficit/hyperactivity disorder. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Emerging Health Technologies 2003 May;(46):4. | Link
  8. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, et al. Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75. | CrossRef | PubMed
  9. Hanwella R, Senanayake M, de Silva V. Comparative efficacy and acceptability of methylphenidate and atomoxetine in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis. BMC Psychiatry. 2011 Nov 10;11:176. | CrossRef | PubMed
  10. Institute for Clinical Systems Improvement. Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. Bloomington: Institute for Clinical Systems Improvement, 2010:72. | Link
  11. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. | CrossRef | PubMed
  12. Kaiser Permanente ADHD Guideline Development Team. Child/adolescent attention deficit/hyperactivity disorder (ADHD) clinical practice guideline. Oakland: Kaiser Permanente Care Management Institute, 2009:338. | Link
  13. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. London: National Institute for Health and Clinical Excellence (NICE), 2008:59. | Link
  14. Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people. A national clinical guideline. Edinburgh, Scotland: Scottish Intercollegiate Guidelines Network (SIGN), 2009:52. | Link